Exact Sciences Corporation
EXAS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 21.43 | 0.23 | -0.00 |
| FCF Yield | 1.84% | 0.46% | -0.00% | 0.10% |
| EV / EBITDA | 252.55 | 224.01 | -269.25 | -15.43 |
| Quality | ||||
| ROIC | -0.48% | -0.04% | -1.83% | -15.81% |
| Gross Margin | 68.64% | 69.35% | 70.82% | 60.16% |
| Cash Conversion Ratio | -11.22 | -75.12 | -0.30 | -0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.61% | 8.52% | 8.73% | 9.80% |
| Free Cash Flow Growth | 307.13% | 12,887.67% | -103.40% | -90.45% |
| Safety | ||||
| Net Debt / EBITDA | 36.44 | 35.09 | -57.05 | -2.64 |
| Interest Coverage | -2.61 | -0.22 | -10.89 | -106.28 |
| Efficiency | ||||
| Inventory Turnover | 1.62 | 1.45 | 1.17 | 1.75 |
| Cash Conversion Cycle | 44.33 | 44.34 | 50.64 | 54.47 |